Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 should be refrigerated. The KB Solution is more effective at delivering RU58841 to the scalp.

Estrogen injections significantly improved hair growth, particularly on the crown, after stopping finasteride. Monotherapy with estrogen led to hairline improvement, but also caused sterility and potential feminization effects.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

The conversation discusses creating a foam version of RU58841 for easier application on thick hair, comparing it to minoxidil foam. The user currently uses dutasteride, minoxidil, and needling for hair loss treatment.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.

Panax ginseng, specifically a ginsenoside-enriched formulation, is suggested as a potential hair growth treatment alongside finasteride and minoxidil. The user is considering trying panax ginseng despite limited availability and evidence.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The user is treating androgenetic alopecia with finasteride and discovered a folic acid deficiency. They are asking if curing the deficiency can worsen or improve their hair condition.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.

Finasteride can cause gynecomastia, which may be reversible by stopping the drug and using selective estrogen receptor modulators (SERMs) like tamoxifen. Lifestyle changes such as weight loss and avoiding alcohol can also help, but surgery may be needed if the condition persists.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

The user experienced increased hair shedding after using RU58841 for two months, but found relief from scalp itchiness. Other users shared similar shedding experiences and discussed side effects like joint pain, while also mentioning the use of finasteride and minoxidil.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

Reishi mushroom is significantly weaker than finasteride for inhibiting 5 alpha reductase, requiring much larger quantities to achieve similar effects. The effectiveness and safety of consuming large amounts of Reishi for hair loss are uncertain.

The conversation discusses hair regrowth using finasteride, minoxidil, and a dermaroller. Users also talk about the benefits of using a stamp over a derma roller for scalp treatment.

Mango oil may inhibit DKK1 and DHT, potentially aiding hair growth by activating the Wnt signaling pathway. A user plans to test mango leaves juice and other Ayurvedic products for hair regrowth.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

RU58841 for hair loss, with users discussing sources, effectiveness, and side effects. Some users report side effects and question the long-term safety of RU58841.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

A user discussed their hair transplant progress and mentioned using 1mg Finasteride, 5% Topical Minoxidil, and recently starting 5% RU58841. They are seeking advice on whether to use RU58841 at month 4 post-transplant.

After gyno surgery, OP is considering restarting finasteride at a lower dose (0.25mg/0.5mg) or switching to topical to reduce the risk of gyno recurrence. Lower doses and topical application may lessen side effects due to reduced systemic absorption.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.